Journal Watch · Journal of Medicinal Chemistry · 2026
Structure-Based Discovery of (<i>E</i>)- and (<i>Z</i>)-4-Oxobut-2-enoate Derivatives as Novel Covalent Pin1 Inhibitors with Antitumor Activity.
Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.
TL;DR
Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.
Key findings
- Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.
What they did
The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors. The SAR investigations resulted in four (<i>Z</i>)-isomers (<b>T29</b>, <b>T39-T41</b>: enzymatic IC<sub>50</sub> = 0.02-0.08 μM) with excellent enzymatic activity, while the (<i>E</i>)-isomer <b>T7</b> (enzymatic IC<sub>50</sub> = 1.54 μM) was found to potently suppress the proliferation of MDA-MB-468 cancer cells by downregulating the Pin1 substrates c-Myc and Cyclin D1.
Full abstract (original)
Background: Peptidyl-prolyl <i>cis</i>-<i>trans</i> isomerase Pin1 is a promising anticancer target that is overexpressed in numerous cancers and associated with poor prognosis. Herein, two series of covalent Pin1 inhibitors featuring an (<i>E</i>)- or a (<i>Z</i>)-4-oxobut-2-enoate moiety as the electrophilic warhead were discovered, and their binding features were revealed by six cocrystal structures.
What they did: The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors. The SAR investigations resulted in four (<i>Z</i>)-isomers (<b>T29</b>, <b>T39-T41</b>: enzymatic IC<sub>50</sub> = 0.02-0.08 μM) with excellent enzymatic activity, while the (<i>E</i>)-isomer <b>T7</b> (enzymatic IC<sub>50</sub> = 1.54 μM) was found to potently suppress the proliferation of MDA-MB-468 cancer cells by downregulating the Pin1 substrates c-Myc and Cyclin D1.
Results & conclusions: Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00041 · PubMed 42388100.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Altogether, 4-oxobut-2-enoate derivatives were disclosed as new templates for further developing potent covalent Pin1 inhibitors.
What type of study is this?
It is a research study, published in Journal of Medicinal Chemistry in 2026. The binding kinetic investigations revealed that both (<i>E</i>)- and (<i>Z</i>)-4-oxobut-2-enoate warheads exhibited an appropriate electrophilic activity (<i>k</i><sub>inact</sub> = 0.006-3.60 min<sup>-1</sup>), conferring them as favorable covalent warheads for developing potent Pin1 inhibitors.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00041. PubMed ID: 42388100. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/structure-based-discovery-of-lt-i-gt-e-lt-i-gt-and-lt-i-gt-z-lt-i-gt-4-o-c00041/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides